Table 1 |
||
|
Rheumatoid arthritis-related parameters and traditional cardiovascular risk factors in subgroups of nondiabetic rheumatoid arthritis patients stratified by the presence of at least one new carotid plaque at follow-up enda |
||
|
New carotid plaque formation during follow-up |
||
|
|
||
|
Parameters |
Yes |
No |
|
|
||
|
Patient demographics |
||
|
Total number of patients |
19 |
45 |
|
Age at follow-up end (years)b |
70.6 ± 6.9 |
59.2 ± 12.1 |
|
Sex, n (%) |
14 women (73.7) 5 men (26.3) |
39 women (86.7) 6 men (13.3) |
|
Months of follow-up (months) |
40.6 ± 3.0 |
40.9 ± 3.0 |
|
RA-related parameters |
||
|
Duration of disease at follow-up end (years) |
9.4 ± 3.9 |
11.9 ± 6.9 |
|
Functional class of disease, n (%) |
||
|
Class I |
12 (63.2) |
18 (40.0) |
|
Class II |
6 (31.6) |
17 (37.8) |
|
Class III |
1 (5.3) |
9 (20.0) |
|
Class IV |
0 (0) |
1 (2.2) |
|
Stage of disease, n (%) |
||
|
Early |
6 (31.6) |
11 (24.4) |
|
Moderate |
12 (63.2) |
19 (42.2) |
|
Severe |
1 (5.3) |
14 (31.1) |
|
Terminal |
0 (0) |
1 (2.2) |
|
RF-positive, n (%) |
13 (68.4) |
29 (64.4) |
|
hs-CRP AUC during follow-up (mg/dl × months) |
16.6 (12.4, 57.5) |
23.8 (12.3, 45.2) |
|
ESR AUC during follow-up (mm/hour × months) |
1,121.1 ± 627.6 |
1,157.0 ± 537.6 |
|
Disease-related treatments (months during follow-up) |
||
|
Nonbiologic DMARDs |
38.4 (35.1, 41.4) |
40.0 (32.6, 42.5) |
|
Biologic agents |
0.0 (0.0, 39.3) |
31.6 (0.0, 41.4) |
|
Corticosteroids |
40.5 (35.2, 42.3) |
33.2 (3.7, 41.7) |
|
Remission during follow-up (months) |
36.2 (32.4, 39.1) |
31.4 (11.3, 37.3) |
|
Remission during follow-up (% of follow-up time) |
90.5 (85.0, 92.9) |
84.6 (27.8, 92.6) |
|
Traditional cardiovascular risk factors |
||
|
Hypertension at baseline, n (%) |
12 (66.7) |
17 (37.8) |
|
SBP AUC during follow-up (mmHg × months) |
5,791.1 ± 634.3 |
5,416.7 ± 599.6 |
|
DBP AUC during follow-up (mmHg × months) |
3,491.4 ± 306.5 |
3,333.9 ± 323.9 |
|
Antihypertensive treatment (% follow-up time) |
2.3 (0, 2.4) |
0 (0, 2.3) |
|
LDL ≥ 160 mg/dl and/or under statin treatment at baseline, n (%) |
8 (42.1) |
12 (26.7) |
|
LDL AUC during follow-up (mg/dl × months) |
5,528.9 ± 1294.1 |
5,457.7 ± 1377.9 |
|
Statin use during follow-up (% follow-up time) |
0.0 (0.0, 29.0) |
0.0 (0.0, 0.0) |
|
Smoking at end of follow-up, n (%) |
7 (36.8) |
14 (31.1) |
|
Total years of smoking |
30 (0.0, 40.0) |
0.0 (0.0, 29.0) |
|
BMI (kg/m2) |
||
|
BMI at baseline |
26.1 ± 3.5 |
25.9 ± 3.7 |
|
BMI at follow-up end |
26.0 ± 3.8 |
26.3 ± 4.4 |
|
Positive family history of CAD, n (%) |
7 (36.8) |
8 (17.8) |
|
Number of CV risk factors, n (%) |
||
|
0 |
0 (0) |
13 (28.9) |
|
1 |
9 (47.4) |
17 (37.8) |
|
2 |
7 (36.8) |
12 (26.7) |
|
3 |
3 (15.8) |
3 (6.7) |
|
Carotid plaques at baseline, n (%) |
14 (73.7) |
16 (35.6) |
|
|
||
|
aAUC: area under the curve, BMI: body mass index, CAD: coronary artery disease, CV: cardiovascular, DBP: diastolic blood pressure, ESR: erythrocyte sedimentation rate, hs-CRP: high-sensitivity C-reactive protein, LDL: low-density lipoprotein, RA: rheumatoid arthritis, SBP: systolic blood pressure. Data are number (%), mean ± SD or median (lower and upper quartiles). bSignificant difference between subgroups after Bonferroni correction for multiple comparisons (P = 0.0084). All other comparisons did not reach significance. |
||
|
Zampeli et al. Arthritis Research & Therapy 2012 14:R44 doi:10.1186/ar3757 |
||
